Furthermore, a phase 1 clinical trial of immunotherapy discovered that administering DCs expressing the CCR7 receptor ligand CCL21 into lung cancers could enhance immunity and cause the tumor to shrink (35). This evidence concerns the gene CCL21 and neoplasm.